Trial Profile
Neoadjuvant chemotherapy with gemcitabine and cisplatin (GC) versus dose-dense methotrexate, vinblastine, doxorubicin and cisplatin (MVAC) in muscle-invasive urothelial carcinoma of the bladder.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 17 Sep 2018
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Doxorubicin (Primary) ; Gemcitabine (Primary) ; Methotrexate (Primary) ; Vinblastine (Primary)
- Indications Urogenital cancer
- Focus Adverse reactions
- 10 Sep 2018 Status changed from recruiting to discontinued.
- 10 Aug 2016 New trial record